Keith-Harrison Dewedoff
Président chez Kaizen Bioscience LLC
Profil
Keith-Harrison Dewedoff is currently the Chairman at Kaizen Bioscience LLC and the Chief Financial Officer at Ceptur Therapeutics, Inc. He previously worked as the Chief Financial Officer at Danforth Advisors LLC and Code Biotherapeutics, Inc. In 2023, he briefly served as the Chief Financial Officer at NLS Pharmaceutics Ltd.
Postes actifs de Keith-Harrison Dewedoff
| Sociétés | Poste | Début |
|---|---|---|
Kaizen Bioscience LLC
 Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Président | - |
Ceptur Therapeutics, Inc.
 Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Directeur Financier/CFO | - |
Anciens postes connus de Keith-Harrison Dewedoff
| Sociétés | Poste | Fin |
|---|---|---|
| NLS PHARMACEUTICS AG | Directeur Financier/CFO | 01/09/2023 |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Directeur Financier/CFO | - |
Danforth Advisors LLC
 Danforth Advisors LLC Miscellaneous Commercial ServicesCommercial Services Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NLS PHARMACEUTICS AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
Danforth Advisors LLC
Danforth Advisors LLC Miscellaneous Commercial ServicesCommercial Services Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Commercial Services |
Kaizen Bioscience LLC
Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |
